There are several inhibitors developed that target IL-8 or its receptors CXCR1 and/or CXCR2 (Table 2), with several ongoing clinical trials in PCa targeting these pathways to evaluate their effectiveness (summarized in Table 3). This evidence concerns the gene CXCR1 and posterior cortical atrophy.